Sanofi-aventis

Sanofi

Michel Finet

Sandor Batori

Zoltan Kapui

Peter Aranyi

Katalin Urban-Szabo

Endre Mikus

Kinga Boer

Geza Timari

Judit Vargane Szeredi

Katalin Gerber

Tibor Szabo

Olivier Venier

Christophe Philippo

Maria Balogh

Edit Susan

Judit Bence

Zsuzsanna Tomoskozi

Katalin Urban Szabo

The present invention relates to the adenosine Areceptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.

Compounds

The present invention relates to an adenosine Areceptor ligand of the general formula (I).

Aminoquinoline derivatives and their use as adenosine A3 ligands

The present invention relates to substituted pyrimidine compounds of formula I useful as orexin receptor antagonists. The invention also relates to pharmaceutical compositions containing said compounds. 

Pyrimidine derivatives as orexin receptor antagonists

The present invention relates to an adenosine Areceptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II&#x2033;), (III&#x2033;), (IV&#x2033;), (V&#x2033;), (VI&#x2033;), (VII&#x2033;), (VIII&#x2033;) and (XIII&#x2033;) and their preparation.

Growing community of inventors

Budapest, Hungary

Michel Finet